The clinical use of IGRT in prostate radiotherapy
13 Mar 2020
The use of IGRT for prostate cancer helps compensate for changes in prostate position predominantly due to physiological rectal and bladder filling. As treatments become more hypofractionated IGRT is essential to reduce geographical miss and minimise toxicity. This talk will review clinical evidence, treatment techniques and imaging protocols for prostate radiotherapy.
Education aims:
• To understand the clinical rationale for prostate IGRT
• To explain IGRT techniques
• To describe imaging protocols and their strengths and limitations
References:
• A randomised assessment of image guided radiotherapy within a phase 3 trial of conventional or hypofractionated high dose intensity modulated radiotherapy for prostate cancer. Julia Murray et al on behalf of CHHiP Investigators. Radiotherapy and Oncology 142 (2020): 62-71.
• ESTRO ACROP consensus guideline on the use of image guided radiation therapy for localized prostate cancer Pirus Ghadjar, Claudio Fiorino, Per Munck af Rosenchold, Michael Pinkawa, Thomas Zilli, Uulke A. van der Heide. Radiotherapy and Oncology 141 (2019): 5-13.
0.5 CPD credit.
Watch the video and complete the online self-reflection form. Go to "My events" to download your certificate. You must login to watch the video and receive CPD.
Education aims:
• To understand the clinical rationale for prostate IGRT
• To explain IGRT techniques
• To describe imaging protocols and their strengths and limitations
References:
• A randomised assessment of image guided radiotherapy within a phase 3 trial of conventional or hypofractionated high dose intensity modulated radiotherapy for prostate cancer. Julia Murray et al on behalf of CHHiP Investigators. Radiotherapy and Oncology 142 (2020): 62-71.
• ESTRO ACROP consensus guideline on the use of image guided radiation therapy for localized prostate cancer Pirus Ghadjar, Claudio Fiorino, Per Munck af Rosenchold, Michael Pinkawa, Thomas Zilli, Uulke A. van der Heide. Radiotherapy and Oncology 141 (2019): 5-13.
0.5 CPD credit.
Watch the video and complete the online self-reflection form. Go to "My events" to download your certificate. You must login to watch the video and receive CPD.
Duration:26 mins
Speaker info
Ann Henry
Ann Henry Consultant Clinical Oncologist, Leeds Teaching Hospitals NHS Trust Ann Henry specialises in the radiation treatment of urological cancers and in 2014 was appointed as an Associate Professor in Clinical Oncology. Her research interests are personalised radiotherapy delivery, radiotherapy clinical trails and patient reported outcomes. She is a member of the ON-TARGET IGRT steering group. She is co-investigator on a number of multicentre CRUK funded radiotherapy clinical trials and Leeds Co-investigator on CRUK funded RADNET Centre of Excellent and Advanced Radiotherapy Technologies Networks.